270574-63-5Relevant academic research and scientific papers
Production method of cimetidine
-
Paragraph 0007; 0026; 0031-0032; 0037-0038; 0043, (2021/08/11)
The invention relates to a production method of cimetidine, the production method comprises the following steps: (1) reacting 2-chloroethanol with thiocyanate to prepare an intermediate (I); (2) reacting the intermediate (I) with methylamine to prepare an intermediate (II); (3) oxidizing the intermediate (II) with oxyacetic acid to obtain an intermediate (III); (4) condensing the intermediate (III) and cyanamide to obtain an intermediate (IV); and (5) condensing the intermediate (IV) and imidazole mercaptan (V) to prepare cimetidine. The production method of cimetidine is provided, the production method can avoid the environmental pollution caused by the by-product methyl mercaptan generated in the existing cimetidine production, and is simple in production process, low in production cost and suitable for industrial production.
Importance of the azole moiety of cimetidine derivatives for the inhibition of human multidrug and toxin extrusion transporter 1 (hmate1)
Shinya, Susumu,Kawai, Kentaro,Tarui, Atsushi,Karuo, Yukiko,Sato, Kazuyuki,Matsuda, Masaya,Kitatani, Kazuyuki,Kobayashi, Naoki,Nabe, Takeshi,Otsuka, Masato,Omote, Masaaki
, p. 905 - 912 (2021/09/06)
Herein, we describe the design and synthesis of cimetidine analogs, as well as their inhibitory activity toward the human multidrug and toxin extrusion transporter 1 (hMATE1), which is related to nephrotoxicity of drugs. Cimetidine is the histamine H2-receptor antagonist, but also inhibits hMATE1, which is known to cause renal impairment. We designed and synthesized cimetidine analogs to evaluate hMATE1 inhibitory activity to reveal whether the analogs could reduce the inhibition of hMATE1. The results showed that all analogs with an unsubstituted guanidino group exhibited hMATE1 inhibitory activity. On the other hand, there was a clear difference in the hMATE1 inhibitory activity for the other compounds. That is, compounds with a methylimidazole ring exhibited hMATE1 inhibition, while compounds with a phenyl ring did not. The results suggest that the ability to form hydrogen bonds at the azole moiety is strongly involved in the hMATE1 inhibition.
Preparation method of cimetidine
-
, (2021/08/06)
The invention discloses a preparation method of cimetidine. The preparation method comprises the following steps of (1) condensing 2-(4-methylimidazole-4-yl) methyl thioethylamine hydrochloride and CS2 in the presence of alkali, and preparing an intermediate (I) under the action of a desulfurization reagent, (2) reacting the intermediate (I) with monomethylamine to prepare an intermediate (II), and (3) in the presence of a desulfurization reagent, carrying out amination on the intermediate (II) and cyanamide to prepare cimetidine.
Preparation method of cimetidine
-
Paragraph 0010; 0033; 0035-0043, (2021/05/26)
The invention provides a preparation method of cimetidine. The method comprises the steps of firstly, converting (5-methyl-1H-imidazole-4-yl) methanol into nitrate of (5-methyl-1H-imidazole-4-yl) methanol, and then reacting with N-cyano-N'-methyl-N''-mercaptoethylguanidine ether to prepare cimetidine. The reaction conditions are mild, the yield is high, by-products are few, the aftertreatment is simple, volatile methyl mercaptan is not generated, the environmental friendliness and safety are greatly improved, and the method is particularly suitable for industrial application to produce cimetidine.
Cimetidine synthesis process
-
Paragraph 0048-0059, (2019/11/12)
The invention relates to the technical field of biomedicine, in particular to a cimetidine synthesis process. The cimetidine synthesis process has high efficiency, damage to the human body and the environment can be reduced, and meanwhile the synthesis cost can be reduced. The synthesis process comprises the following steps: (1) mixing a first intermediate with a photocatalyst, and dissolving theobtained mixture in a reaction solvent; (2) adding a second intermediate to the reaction solution obtained in the step (1), and performing uniform mixing so as to obtain a clear solution; (3) using alight source to irradiate the clear solution obtained in the step (2), and performing coordinated stirring until it is shown through HPLC that the first intermediate reacts completely; and (4) performing concentration treatment so as to remove the solvent after completion of the reaction, and performing recrystallization by using water and isopropanol or ethanol so as to obtain cimetidine white powder.
Floating pharmaceutical composition comprising an active phase and a non-active phase
-
, (2010/04/23)
The invention concerns a floating pharmaceutical composition consisting of at least a first phase comprising at least a high dose active principle combined with one or several carriers and at least a second phase comprising at least a gas-generating system. The invention also concerns tablets comprising such a pharmaceutical composition and a method for preparing such tablets.
Cimetidine granules coated with a partially hydrogenated vegetable oil
-
, (2008/06/13)
A non-aqueous, chewable composition for oral delivery of unpalatable drugs is provided. The composition contains the drug intimately dispersed or dissolved in a pharmaceutically acceptable lipid that is solid at room temperatures. The composition also has a matrix that contains a granulating agent for the total composition and a rapid dispersal agent and optionally additives such as buffering agents, flavoring agents, surfactants and the like.
Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
-
, (2008/06/13)
In accordance with this invention there is provided a granular product with an effervescent system which comprises acid-sensitive pharmaceutically active substances, such as, for example, beta-carotene, cimetidine, ranitidine or cisapride, which is specially useful to prevent antacid action, having an acid-binding capacity below about 5meq, at a weight of about 1.6 to about 2.3 grams. The effervescent grains are made from carrier crystals of at least one solid, edible organic acid, preferably citric acid, and are present as a granular product, separate from the pharmaceutically active substance, and are coated with at least one layer of a water-soluble neutral substance which is able to bring about a melting point depression of the acid grains at their surface, such as, for example, a water-soluble polymer, a higher alcohol, a carbohydrate and/or a hydrocolloid. A second coating contains at least a part of the alkali and/or alkaline earth carbonate or bicarbonate provided for the total dosage.
Solid pharmaceutical compositions for oral administration with prolonged gastric residence
-
, (2008/06/13)
Solid pharmaceutical compositions for oral administration, with prolonged residence in the stomach, consisting of one or more high density inorganic substances, one or more bioadhesive substances, an active ingredient - either as it is or mixed in a carrier system - as well as excipients, binders, lubricants and other materials commonly used in pharmaceutical formulations.
